Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply

Aliment Pharmacol Ther. 2017 May;45(10):1372. doi: 10.1111/apt.14060.

Authors

Y Komaki¹, A Yamada¹, F Komaki¹, D Micic², A Ido³, A Sakuraba¹

Affiliations

¹ Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA.
² Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
³ Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

PMID: 28417494
DOI: 10.1111/apt.14060

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal
Biosimilar Pharmaceuticals*
Humans
Inflammatory Bowel Diseases
Infliximab*
Tumor Necrosis Factor-alpha

Substances

Antibodies, Monoclonal
Biosimilar Pharmaceuticals
CT-P13
Tumor Necrosis Factor-alpha
Infliximab